Researchers uncover new target to stop cancer growth

June 21, 2018

Researchers at the University of Wisconsin-Madison have discovered that a protein called Munc13-4 helps cancer cells secrete large numbers of exosomes--tiny, membrane-bound packages containing proteins and RNAs that stimulate tumor progression. The study, which will be published June 21 in the Journal of Cell Biology, could lead to new therapies that stop tumor growth and metastasis by halting exosome production.

Cancer cells produce large numbers of exosomes, which contribute to tumor progression in many different ways. They can transfer cancer-causing oncogenes to neighboring cells to increase their proliferation; they can contain proteins that reorganize the cancer cells' surroundings and allow them to spread to other tissues; and they can contain signaling factors that disrupt the body's ability to mount an immune response against the tumor.

A team led by Thomas F.J. Martin of the University of Wisconsin-Madison with Scott W. Messenger as lead author found that calcium--which is often increased in cancer cells--stimulated the secretion of exosomes from aggressive breast cancer cells. Exosome release depended on a calcium-binding protein called Munc13-4; removing this protein, or replacing it with a mutant version unable to bind calcium, prevented breast cancer cells from releasing exosomes in response to calcium.

Munc13-4 levels are often elevated in human breast, pancreatic, and lung tumors. Martin and colleagues found that lung and pancreatic cancer cells increased their levels of Munc13-4 and released more exosomes as they became more aggressive.

Exosomes are formed inside large cellular organelles called multivesicular bodies. These organelles then fuse with the cell's plasma membrane to release exosomes outside of the cell. Messenger et al. found that Munc13-4 works with another protein called Rab11 to promote the development of multivesicular bodies capable of fusing with the plasma membrane and releasing exosomes.

Exosomes released from cancer cells carry an enzyme called MT1-MMP, which degrades the extracellular matrix surrounding cancer cells. This helps the cancer cells disperse around the body to form secondary metastatic tumors.

When Martin and colleagues depleted Munc13-4, they reduced the release of MT1-MMP-containing exosomes from breast cancer cells and inhibited the cells' ability to degrade the extracellular matrix.

"Overall, we think that increased expression of Munc13-4, combined with elevated calcium levels, drives enhanced exosome release by highly aggressive cancer cells, and that Munc13-4 is a potential target for therapeutic intervention," Martin says.
-end-
Messenger et al., 2018. J. Cell Biol.http://jcb.rupress.org/cgi/doi/10.1083/jcb.201710132?PR

About the Journal of Cell Biology

The Journal of Cell Biology (JCB) features peer-reviewed research on all aspects of cellular structure and function. All editorial decisions are made by research-active scientists in conjunction with in-house scientific editors. JCB makes all of its content free online no later than six months after publication. Established in 1955, JCB is published by the Rockefeller University Press. For more information, visit jcb.org.

Visit our Newsroom, and sign up for a weekly preview of articles to be published. Embargoed media alerts are for journalists only.

Follow JCB on Twitter at @JCellBiol and @RockUPress.

Rockefeller University Press

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.